Europe Peptic Ulcer Drugs Market

Europe Peptic Ulcer Drugs Market Size (2022 to 2027)

The Europe Peptic ulcer drugs Market was worth USD 1.45 billion in 2022 and is estimated to be growing at a CAGR of 1.85%, to reach USD 1.58 billion by 2027.

A peptic ulcer is a breakage in the inner surface of the stomach or the upper part of the intestine in the gastrointestinal tract. Ulcers form when the protective wall of the intestine or stomach is broken. 

The increase in the consumption of NSAIDs due to the increasing prevalence of inflammatory diseases is the major driver for the growth of the Europe peptic ulcer drugs market. Other factors deciding the market growth include an increase in the uptake of peptic ulcer drugs form any painful procedures, changes in disease management and treatment modalities, the prevalence of ulcers associated with stress due to higher smoking rates, availability of affordable treatment due to improved healthcare infrastructure, awareness of the disease, etc.

The increase in the geriatric population, the increase in the prevalence of peptic ulcers due to the change in dietary habits, and the increase in the consumption of tobacco and alcohol are causing a significant increase in people suffering from ulcers and anti-ulcer drugs market in Europe. In addition, increasing R&D for new drug development, availability of cost-effective drugs, and increased healthcare expenditure will increase the European peptic ulcer drugs market over the forecasted years. Technological improvements in diagnostic techniques such as gastroscopy and biopsy, and increased funding from government agencies in the health system are driving the growth of the Europe peptic ulcer drugs market.

However, Side effects with long-term peptic ulcer drugs use are a major factor restraining the growth of the market in Europe. Additionally, complications due to the expiration of drugs blocking patents, lack of research and development in the field, and changes in pricing policies across European nations are hampering the growth of the Europe peptic ulcer drug market.

This research report on the Europe peptic ulcer drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Proton Pump Inhibitors (PPIs)
• Anti-Histamines
• H2 Antagonists
• Antacids
• Antibiotics
• Others

By Ulcer Type:

• Gastric Ulcers
• Duodenal Ulcer
• Esophageal Ulcer

By Country:

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands and
• Rest of Europe

The Europe peptic ulcer drugs market is growing at a faster rate with substantial growth rates in recent years and the market is expected to grow significantly during the studied period. With the stimulation of national industrial policy and support due to technological advancements, the European peptic ulcer drug market is developing rapidly in the field of research and development.

In Europe, Germany is expected to grow by around 5.8% CAGR. Germany was worth $ 170 million in 2020 and is expected to have the largest market share in the upcoming years. The German market growth is owing to the increased incidences of peptic ulcers in the country, which is driving the growing demand for the drugs in the region. On the other hand, the UK is expected to occupy the second position during the forecast period. This is attributable to factors such as the increase in healthcare spending for the period between 2020 and 2027.

Lucrative growth was seen in the European peptic ulcer drug market attributed to increased tobacco and alcohol consumption, high use of peptic ulcer drugs in various surgeries, and long-term use of various drugs, such as pain relievers that cause peptic ulcers, market. However, the peptic ulcer drug market in UK and France is driven by the influx of generic drugs due to the expiration of patents, the increase in medical tourism for various surgeries, and a large number of patients due to increasing geriatric population gather market revenues.

KEY MARKET PLAYERS:

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB and Eumedica Pharmaceuticals are some of the companies currently dominating the Europe peptic ulcer drugs market and profiled in this report.